Conferences - Results from #8000

EAU 2017: Circulating Tumor Cells in Prostate Cancer: A Marker? March 25, 2017

EAU 2017: The role of surgery in metastatic renal cancer March 25, 2017

EAU 2017: Observation or active surveillance or curative treatment: What do SPCG-4 data tell us? March 25, 2017

EAU 2017: Prospective validation of active surveillance: PRIAS March 25, 2017

EAU 2017: Observation or active surveillance or curative treatment: What do PIVOT data tell us? March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Imaging-based biomarkers: mpMRI March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Tissue-based biomarkers: CCP March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Blood and urine-based biomarkers March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: The role of miRNA in oncogenesis and progression March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Dietary and lifestyle factors March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group: PLCO March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group: ERSPC March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group: ProtecT March 25, 2017

EAU 2017: Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial March 25, 2017

EAU 2017: Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial March 25, 2017

EAU 2017: Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder March 25, 2017

EAU 2017: Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Urologist’s Perspective on Active Surveillance March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Imaging Specialist’s Perspective on MRI March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Pathologist’s Perspective March 24, 2017

Page 401 of 507